OBJECTIVE: The purpose of this study was to assess whether CAM use affected breast cancer prognosis in those who did not receive systemic therapy. DESIGN: Secondary data analysis of baseline/survey data from the Women's Healthy Eating and Living (WHEL) study. 2562 breast cancer survivors participating in the study completed baseline assessments and a CAM use questionnaire. Cox regression models were conducted to evaluate the use of CAM modalities and dietary supplements on time to an additional breast cancer event (mean follow-up=7.3 years). SETTING: A US-based multi-site randomized dietary trial. OUTCOME: Time to additional breast cancer events. RESULTS: The women who did not receive any systemic treatment had a higher risk for time to additional breast cancer events (HR=1.9, 95% CI: 1.32, 2.73) and for all-cause mortality (HR=1.7, 95% CI: 1.06, 2.73) compared to those who had received systemic treatment. Among 177 women who did not receive systemic treatment, CAM use was not significantly related to additional breast cancer events. There were no significant differences between high supplement users (≥3 formulations per day) and low supplement users in either risk for additional breast cancer events. CONCLUSION: The risk for an additional breast cancer event and/or death was higher for those who did not receive any systemic treatments; the use of dietary supplements or CAM therapies did not change this risk. This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment.
RCT Entities:
OBJECTIVE: The purpose of this study was to assess whether CAM use affected breast cancer prognosis in those who did not receive systemic therapy. DESIGN: Secondary data analysis of baseline/survey data from the Women's Healthy Eating and Living (WHEL) study. 2562 breast cancer survivors participating in the study completed baseline assessments and a CAM use questionnaire. Cox regression models were conducted to evaluate the use of CAM modalities and dietary supplements on time to an additional breast cancer event (mean follow-up=7.3 years). SETTING: A US-based multi-site randomized dietary trial. OUTCOME: Time to additional breast cancer events. RESULTS: The women who did not receive any systemic treatment had a higher risk for time to additional breast cancer events (HR=1.9, 95% CI: 1.32, 2.73) and for all-cause mortality (HR=1.7, 95% CI: 1.06, 2.73) compared to those who had received systemic treatment. Among 177 women who did not receive systemic treatment, CAM use was not significantly related to additional breast cancer events. There were no significant differences between high supplement users (≥3 formulations per day) and low supplement users in either risk for additional breast cancer events. CONCLUSION: The risk for an additional breast cancer event and/or death was higher for those who did not receive any systemic treatments; the use of dietary supplements or CAM therapies did not change this risk. This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment.
Authors: Angela Fagerlin; Indu Lakhani; Paula M Lantz; Nancy K Janz; Monica Morrow; Kendra Schwartz; Dennis Deapen; Barbara Salem; Lihua Liu; Steven J Katz Journal: Patient Educ Couns Date: 2006-07-24
Authors: Brian N Fink; Mia M Gaudet; Julie A Britton; Page E Abrahamson; Susan L Teitelbaum; Judith Jacobson; Paula Bell; Joyce A Thomas; Geoffrey C Kabat; Alfred I Neugut; Marilie D Gammon Journal: Breast Cancer Res Treat Date: 2006-03-15 Impact factor: 4.872
Authors: Robert M Reed; Anna W Reed; Patrick F McArdle; Michael Miller; Toni I Pollin; Alan R Shuldiner; Nanette I Steinle; Braxton D Mitchell Journal: J Acad Nutr Diet Date: 2014-10-12 Impact factor: 4.910
Authors: Carolin C Hack; Peter A Fasching; Tanja Fehm; Johann de Waal; Mahdi Rezai; Bernd Baier; Gerold Baake; Hans-Christian Kolberg; Martin Guggenberger; Mathias Warm; Nadia Harbeck; Rachel Wuerstlein; Jörg-Uwe Deuker; Peter Dall; Barbara Richter; Grischa Wachsmann; Cosima Brucker; Jan W Siebers; Nikos Fersis; Thomas Kuhn; Christopher Wolf; Hans-Walter Vollert; Georg-Peter Breitbach; Wolfgang Janni; Robert Landthaler; Andreas Kohls; Daniela Rezek; Thomas Noesslet; Gunnar Fischer; Stefan Henschen; Thomas Praetz; Volker Heyl; Thorsten Kühn; Thomas Krauss; Christoph Thomssen; Andre Hohn; Hans Tesch; Christoph Mundhenke; Alexander Hein; Claudia Rauh; Christian M Bayer; Adib Jacob; Katja Schmidt; Erik Belleville; Peyman Hadji; Sara Y Brucker; Diethelm Wallwiener; Sherko Kümmel; Matthias W Beckmann; Daniela Paepke Journal: Integr Cancer Ther Date: 2016-09-14 Impact factor: 3.279
Authors: Heather Greenlee; Marilyn L Kwan; Isaac J Ergas; Garrett Strizich; Janise M Roh; Allegra T Wilson; Marion Lee; Karen J Sherman; Christine B Ambrosone; Dawn L Hershman; Alfred I Neugut; Lawrence H Kushi Journal: BMC Cancer Date: 2014-05-29 Impact factor: 4.430